Q Therapeutics and REPROCELL have announced the formulation of MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the CNS.   “MAGiQ Therapeutics aims to bring this promising cell therapy product to market first in a favorable regulatory environment and to begin treating patients as soon as possible,” sa...